European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy for the Treatment of HIV in Pediatric Populations Read more
C4XD signs exclusive global licence worth up to $402 million with AstraZeneca for the development and commercialisation of NRF2 Activator programme Read more
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline Read more
GARDP and Mitsubishi Tanabe Pharma Corporation announce partnership in search for new antibiotics Read more
AbbVie Announces European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Active Crohn’s Disease Read more
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect Formulation of Teprotumumab Read more